deutetrabenazine — Highmark

Initial criteria

• age ≥ 18 years
• diagnosis of chorea associated with Huntington’s disease (ICD-10: G10)

Reauthorization criteria

• prescriber attests that the member has experienced positive clinical response to therapy

Approval duration

12 months